The government has announced $130 million in federal funding to subsidise two asthma medications on the Pharmaceutical Benefits Scheme (PBS). The anti-interleukin-5 (anti-IL-5) therapy mepolizumab (Nucala® Glaxo SmithKline) is now available on the PBS under section 100 as an add-on treatment for people aged 12 and over with severe refractory eosinophilic asthma. It is given ...
Already a member?
Enter your email to keep reading.